Overview

 

Boston Scientific’s innovative products designed for use by Oncologists may provide options for cancer patients who require less invasive treatments. Boston Scientific is currently conducting the Prometheus Study, which is the first large clinical study investigating treatments for metastatic cancer that has spread to the liver.

RF 3000™ Radiofrequency Ablation System and RF Needle Electrode Families are intended for the thermal coagulation necrosis of soft tissues, including partial or complete ablation of nonresectable liver lesions. The RF3000 Radiofrequency Ablation System is an impedance-based feedback system. LeVeen™ Needle Electrodes are meant for open, laparoscopic or percutaneous radiofrequency ablation, providing a cannula and a patented array design that is available in a choice of diameters. The Soloist™ Single Needle Electrode is meant for the treatment of small, difficult-to-access lesions. Caution: The effectiveness of these devices for the use in the treatment of liver cancer or liver disease (i.e., improved clinical outcomes) has not been established.

Renegade™ Hi-Flo Microcatheter
Setting the Standard of Performance in .027" I.D. microcatheters, the Renegade Hi-Flo Microcatheter is meant for distal access and intended for exceptional flow. Its .027" inner lumen is meant to provide high flow delivery of viscous embolic materials, therapeutic agents and increased infusion pressures, further enhancing flow.

Fathom™ .16” Steerable Guidewire
The Fathom Steerable Guidewire combines a nitinol hypotube distal segment with advanced microfabrication technology, creating a design meant to allow access to tortuous vasculature. Unlike conventional guidewires, the nitinol hypotube distal segment is meant to transmit turn-for-turn torque to enhance responsiveness and maneuverability.

Always refer to the directions for use of the products cited for complete instructions and warnings.